secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001193125-23-142023
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero Therapeutics reports Q1 2023 net loss of $13.3M; provides pipeline updates for SPR720, tebipenem HBr, and SPR206
--------------------------------------------------------------------------------

- Net loss of $13.3M ($0.25 per share) in Q1 2023, compared to net loss of $32.8M ($1.01 per share) in Q1 2022.
- Cash and cash equivalents of $96.3M as of March 31, 2023; company expects sufficient funding beyond 2024.
- SPR720 Phase 2 trial in NTM-PD on track for top line data readout in first half of 2024.
- Tebipenem HBr: SPA agreement update expected mid-2023; Phase 3 cUTI trial initiation expected in 2H 2023.
- SPR206: IND submission for Phase 2 trial in hospital-acquired/ventilator-associated bacterial pneumonia expected Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312523142023/0001193125-23-142023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312523142023/d438048d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-142023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer